Grants and Contracts Details
Description
Arginase, a urea cycle enzyme that metabolizes arginine to ornithine, is an
enzyme expressed in cells and tissues throughout the body. However, the urea cycle is
incomplete in non-hepatic cells. Evidence produced by our group at University of
Kentucky and others indicates that arginase in non-hepatic cells depletes arginine from
tissue culture. Arginine is essential for normal cellular immunity as measured by Tlymphocyte
proliferation and surface receptor expression. Therefore, non-hepatic
arginase may contribute to immune dysfunction by depleting arginine.
Trauma patients and surgical patients who receive blood transfusions lose normal
cellular immunity. Arginine enhanced diets in the trauma and elective surgery patient has
been shown to improve outcomes. The mechanisms for this are not well elucidated. Red
blood cells contain a large amount of arginase that may become soluble in solution when
packed red blood cells (PRBC) are stored, similar to the manner in which potassium
levels increase. This, combined with the preliminary work above, supports the hypothesis
that PRBC-induced immune dysfunction may occur through arginine depletion by soluble
arginase in the donor unit.
To begin testing this hypothesis, we have obtained samples of donor PRBC units
(PRBCu). Plasma was separated by centrifugation and plasma arginase was measured as
ornithine production. Healthy donor plasma was used as a comparison (Figure). PRBC
plasma arginase activity was significantly greater (I8-fold) than control plasma.
Status | Finished |
---|---|
Effective start/end date | 7/1/04 → 6/30/05 |
Funding
- Southern Medical Association: $1,225.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.